[Clinical evaluation of enterosorption in the treatment of diabetics].
The internal use of carbon containing sorbents (enterosorption) in the treatment of patients with diabetes mellitus accelerates metabolic compensation and helps to decrease a dose of sugar reducing agents. The antiatherogenic mechanisms are activated, expressed in a decrease in the level of total cholesterol, triglycerides, lipids, the atherogenicity index and an increase in cholesterol in high density lipoproteins. The use of enterosorbents in the treatment of patients with disturbed cardiac rhythm reduces the time of treatment and eliminates the side-effects of antiarrhythmic drugs.
D000328:Adult; D002606:Charcoal / Q000627:therapeutic use; D002908:Chronic Disease; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000628:therapy*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008722:Methods; D008875:Middle Aged
D002606:Charcoal
Klinicheskaia otsenka énterosorbtsii v lechenii bol'nykh sakharnym diabetom.